new FDA advisory on the erythropoietin analogues Procrit, Epogen, and Aranesp
January 2007
Read important updated information from the FDA
You'll hear about a new FDA advisory on the erythropoietin analogues Procrit, Epogen, and Aranesp.
It's based on evidence of an increase in death and cardiovascular events when these drugs are used to boost hemoglobin above 12 g/dL.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote